Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Materials Today. Bio|May 27, 2022
Bioactive cytomembrane@poly(citrate-peptide)-miRNA365 nanoplatform with immune escape and homologous targeting for colon cancer therapyLong Zhang, Wan Zhang, Hang Peng, et al.
Frontiers in Immunology|May 26, 2023
TMBserval: a statistical explainable learning model reveals weighted tumor mutation burden better categorizing therapeutic benefitsYixuan Wang, Jiayin Wang, Wenfeng Fang, et al.
The International Journal of Biochemistry & Cell Biology|February 25, 2024
Identification and validation of LINC01322 as a potential prognostic biomarker and oncogene promoting tumor progression in lung adenocarcinomaLizhong Zeng, Ke Mi, Lei Peng, et al.
Free Radical Biology & Medicine|February 25, 2026
LINC01116 promotes glycolysis by up-regulating HIF-1α via YBX1-mediated dual mechanism in lung cancerXinghui Wang, Xiao Li, Ruiying Sun, et al.
Briefings in Bioinformatics|December 16, 2024
THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured dataYixuan Wang, Yanfang Guan, Xin Lai, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2006
Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancerYue Chen, Hao Zhang, Anjian Xu, et al.
Cellular and Molecular Life Sciences : CMLS|December 30, 2025
Targeting IQGAP3 skews macrophages polarization towards M1 phenotype and promotes antitumor immune responseXiao Li, Xiaopeng An, Yuanyi Zhang, et al.
American Journal of Translational Research|May 18, 2016
The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinibYuping Zhang, Xia Meng, Hongyang Shi, et al.
Open Medicine (Warsaw, Poland)|May 5, 2025
Pathogen surveillance and risk factors for pulmonary infection in patients with lung cancer: A retrospective single-center studyHu Shan, Jing Wang, Qiuhong Zhang, et al.
Thoracic Cancer|March 11, 2022
Pretreatment HDL-C and ApoA1 are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with TKIJuan Ma, Ying Bai, Mei Liu, et al.
Pageof 11